Abstract:Ovarian cancer (OVCA) patients often develop tolerance to standard platinum therapy that accounts for extensive treatment failures. Cisplatin resistant OVCA cells (cis-R) display enhanced survival mechanisms to cope with therapeutic stress. In these cells, increased autophagy process assists in chemoresistance by boosting the nutrient pool under stress. To improve the treatment response, both protective autophagy inhibition and its overactivation are showing efficacy in chemosensitization. Autophagy requires a tightly regulated intracellular pH. Vacuolar ATPases (V-ATPases) are proton extruding nanomotors present on cellular/vesicular membranes where they act as primary pH regulators. V-ATPase ‘a2’ isoform (V0a2), the major pH sensing unit, is markedly overexpressed on the plasma membrane and the early endosomes of OVCA cells. Previously, V0a2 inhibition sensitized cis-R cells to platinum drugs by acidifying cytosolic pH that elevated DNA damage. Here, we examined how V0a2 inhibition affected endosomal function and the autophagy process as a possible factor for cisplatin sensitization. Clinically, V0a2 expression was significantly higher in tissues from drug nonresponder OVCA patients compared to treatment responders. In vitro V0a2 knockdown in cis-R cells (sh-V0a2-cisR) significantly reduced the tumor sphere-forming ability and caused complete disintegration of the spheres upon cisplatin treatment. The apoptotic capacity of sh-V0a2-cisR improved substantially with potentiation of both intrinsic and extrinsic apoptotic pathway when treated with cisplatin. Unlike the chemical V-ATPase inhibitors that acutely induce autophagy, here, the stable V0a2 inhibition dampened the protective autophagy process in sh-V0a2-cisR cells with downregulated expression of proteins beclin-1, ATG-7, and LC3B and low autophagosome numbers compared to control cis-R cells. These cells showed downregulated ERK/MEK pathway that is known to repress autophagy. Interestingly, upon cisplatin treatment of sh-V0a2-cisR, the autophagy initiation proteins (LC3B, ATG7, and Beclin 1) were found upregulated as a stress response compared to the untreated cells. However, there was a concomitant downstream autophagosome accumulation and an enhanced P62 protein levels indicating the overall block in autophagy flux. Mechanistically, V0a2 knockdown caused defects in early endosome function as the transferrin internalization was impaired. Taken together, this study provides a novel insight into the mechanism by which V-ATPase-isoform regulates autophagy that assists in chemoresistance in ovarian cancer. We conclude that V-ATPase-V0a2 is a potent target for developing an effective treatment to enhance patient survival rates in ovarian cancer.

Cancer-ATPases as a New Strategy against + Targeting Vacuolar H Updated

Targeting vacuolar H+-ATPases as a new strategy against cancer.

Targeting tumor acidic microenvironment as a new strategy against cancer

Studies of Proton Pump Inhibitors and Tumor Resistance to Antitumor Drugs

Silencing Of Atp6v1c1 Prevents Breast Cancer Growth And Bone Metastasis

Expression and Functional Role of Vacuolar H(+)-ATPase in Human Hepatocellular Carcinoma.

Small Interfering RNA Targeting the Subunit ATP6L of Proton Pump V-ATPase Overcomes Chemoresistance of Breast Cancer Cells

Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer

The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis

The curious case of vacuolar ATPase: regulation of signaling pathways

In vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses

Atp6v1c1 Facilitates Breast Cancer Growth and Bone Metastasis through the mTORC1 Pathway

Recent Advances of Vacuolar Protein-Sorting 34 Inhibitors Targeting Autophagy

Small Interfering RNA Targeting the Subunit ATP6L of Proton Pump V-ATPase Suppresses the Invasion of Breast Cancer Cells in Vitro

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

The mechanism underlying the effects of the cell surface ATP synthase on the regulation of intracellular acidification during acidosis.

VDAC Modulation of Cancer Metabolism: Advances and Therapeutic Challenges

Targeting Na+/K+‐translocating Adenosine Triphosphatase in Cancer Treatment

Targeting Cancer Cell Mitochondria As a Therapeutic Approach: Recent Updates

Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway

ATP Suppression by Ph-Activated Mitochondria-Targeted Delivery of Nitric Oxide Nanoplatform for Drug Resistance Reversal and Metastasis Inhibition.